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Background: WNT signaling pathways are significantly altered during cancer development. Vertebrates possess two
classes of WNT signaling pathways: the “canonical” WNT/β-catenin signaling pathway, and the “non-canonical”
pathways including WNT/Ca2+ and WNT/Planar cell polarity [PCP] signaling. WNT4 influences hematopoietic
progenitor cell expansion and survival; however, WNT4 function in cancer development and the resulting
implications for oncogenesis are poorly understood.
The aim of this study was twofold: first, to determine the expression of WNT4 in mature peripheral blood cells and
diverse leukemia-derived cells including cell lines from hematopoietic neoplasms and cells from patients with
leukemia; second, to identify the effect of this ligand on the proliferation and apoptosis of the blast-derived cell
lines BJAB, Jurkat, CEM, K562, and HL60.
Methods: We determined WNT4 expression by quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) in peripheral blood mononuclear cells (PBMCs) and T- and B-lymphocytes from healthy individuals, as
well as from five leukemia-derived cell lines and blasts derived from patients with leukemia. To analyze the effect of
WNT4 on cell proliferation, PBMCs and cell lines were exposed to a commercially available WNT4 recombinant
human protein. Furthermore, WNT4 expression was restored in BJAB cells using an inducible lentiviral expression
system. Cell viability and proliferation were measured by the addition of WST-1 to cell cultures and counting cells;
in addition, the progression of the cell cycle and the amount of apoptosis were analyzed in the absence or pres-
ence of WNT4. Finally, the expression of WNT-pathway target genes was measured by qRT-PCR.
Results: WNT4 expression was severely reduced in leukemia-derived cell lines and blasts derived from patients with
leukemia. The exposure of cell lines to WNT4 recombinant protein significantly inhibited cell proliferation; inducing
WNT4 expression in BJAB cells corroborated this observation. Interestingly, restoration of WNT4 expression in BJAB
cells increased the accumulation of cells in G1 phase, and did not induce activation of canonical WNT/β-catenin
target genes.
Conclusions: Our findings suggest that the WNT4 ligand plays a role in regulating the cell growth of leukemia-
derived cells by arresting cells in the G1 cell cycle phase in an FZD6-independent manner, possibly through
antagonizing the canonical WNT/β-catenin signaling pathway.
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WNT pathways direct the specific activation of sets of
genes regulating a plethora of cellular responses such as
cell growth, differentiation, movement, migration, polar-
ity, cell survival, and immune response. Chronic activa-
tion of gene transcription resulting from aberrant
activation of WNT pathways has pathological conse-
quences, and can contribute to tumorigenesis [1-3].
Signaling is initiated when WNT ligands bind to Friz-
zled (FZD) family receptors, activating a canonical sig-
naling pathway in which the central player is a
cytoplasmic protein called β-catenin. WNT ligands also
activate the so-called “non-canonical” pathways that are
β-catenin-independent. These non-canonical pathways
include the planar cell polarity (PCP) pathway that stim-
ulates cytoskeletal reorganization, and the WNT-Ca2+
pathway that leads to calcium mobilization [4]. In
addition to FZD, several other receptors and co-
receptors have been implicated in triggering WNT sig-
naling, including LDL-related protein (LRP), receptor
tyrosine kinase-like orphan receptor (ROR), receptor-
like tyrosine kinase (RYK), and protein tyrosine kinase 7
(PTK7) [2,5,6]. WNT signaling has been implicated in
the regulation of oncogenic growth in leukemias of both
myeloid and lymphoid lineages [7,8]. The canonical
WNT/β-catenin signaling pathway has shown to exert a
positive effect on the control of hematopoietic cell pro-
liferation, survival, and differentiation. However, abnor-
mal activation of the WNT/β-catenin signaling pathway
has been linked to the pathogenesis of many carcinomas
and hematological malignancies [9-12].
Non-canonical pathways are more often associated
with negative control of the proliferation and induction
of cell differentiation [13]. In this sense, antagonism be-
tween the canonical and the non-canonical pathways
may be an essential mechanism for preventing dysregu-
lated self-renewal and oncogenesis.
WNT4 is a ligand that plays an important role in sur-
vival and hematopoietic progenitor cell expansion
through non-canonical signals [14,15]. In addition, non-
canonical WNT4 signals may be critical in preventing
tumor initiation by controlling EAF1 and EAF2/U19 ex-
pression in zebrafish and mammals [16]. In contrast,
WNT4 canonical signals aid in maintaining cell growth
and survival in kidney epithelial cells [17]. Several re-
ports have been published describing the low expression
of WNT4 in cells derived from solid tumor compared
with normal cells [18-20].
Variations in WNT gene expression and the related
signaling molecules have been reported in hematological
cancers [21-23]. However, the function of WNT4 in
leukemia, to our knowledge, has not yet been described;
therefore, the goal of our research was to determine the
expression of the WNT4 ligand in leukemia-derivedcells, the effect of its expression on cell growth and
apoptosis, and the WNT signaling pathway activated in
our cell model.
Results
WNT4 is poorly expressed in leukemia-derived cells
Because WNT4 expression has been related with the
hematopoietic cell proliferation and differentiation, we
wanted to know whether abnormal immature leukemic
cells express WNT4. To do this, we analyzed WNT4 ex-
pression in BJAB, Jurkat, CEM, K562, and HL60 leukemia-
derived cells. We compared the WNT4 expression in these
cells with the usual level of expression found in peripheral
blood mononuclear cells (PBMCs) from healthy volunteers.
We obtained complementary DNA (cDNA) from the
leukemia-derived cells and the healthy PBMCs, and deter-
mined expression of WNT4 by quantitative Reverse
transcriptase-Polymerase chain reaction (qRT-PCR) in all
samples. We used beta actin (ACTB), ribosomal protein
L32 (RPL32), and ribosomal protein S18 (RPS18) as refer-
ence genes to normalize all values. Relative expression ana-
lysis was performed, setting the expression values from the
PBMCs of one of the healthy volunteers as 1 (C1). As can
be observed in Figure 1A, Jurkat and CEM cells, both of
lymphoid origin, exhibit low expression of WNT4 relative
to C1 and C2, with relative values of 0.252 and 0.142, re-
spectively. The lymphoblast-B BJAB cell line and myeloid
types K562 and HL60 had the lowest expression, exhibiting
nearly undetectable levels of WNT4 (0.045, 0.013 and
0.032, respectively) when compared with that of the
controls.
To corroborate our observations, we analyzed WNT4
protein levels by western blot analysis in the leukemia-
derived cell lines, and included protein obtained from
two healthy individuals (PBMC1 and PBMC2) as con-
trols (Figure 1B). We were able to detect a specific band
of approximately 39KD that corresponded with the pre-
dicted weight for WNT4, mainly observed in the
PBMCs; the WNT4 band was very weak in Jurkat, CEM,
K562, and HL60 cell lines. We also probed for ACTB,
beta 2 microglobulin, and α tubulin in the same blot to
control for protein loading. Taken together, these results
show that WNT4 expression in leukemia-derived cell
lines is significantly decreased when compared with that
of mature immune-system cells from clinically healthy
individuals.
WNT4 expression in T- and B-cells from healthy individ-
uals and bone marrow cells from patients with leukemia
After demonstrating that WNT4 expression is strongly
reduced in leukemia-derived cell lines, we wanted to de-
termine whether WNT4 expression is also reduced in
the bone marrow (BM) samples of patients with
leukemia. Due to the origin of leukemia cell lines
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Figure 1 (See legend on next page.)
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Figure 1 WNT4 expression in healthy and leukemia-derived cells. A) Relative expression levels of WNT4 were measured by qRT-PCR in PBMCs
obtained from healthy volunteers (PBMC) and leukemia-derived cells lines (Jurkat, CEM, HL60, K562, and BJAB). An expression value of the PBMCs
of one individual was set as 1. Analysis was calculated using ribosomal Protein L32 (RPL32), ribosomal Protein S18 (RPS18), and beta actin (ACTB)
as reference genes. The graphic depicts the means and subsequent standard deviations (SD) obtained with all reference genes. B) Western blot
assay showing the presence of WNT4 protein in PBMCs from two healthy individuals and leukemia-derived cells lines. ACTB, beta 2 microglobulin,
and α tubulin were used as protein loading controls. C) Box plot graphic showing relative expression levels of WNT4 measured by qRT-PCR nor-
malized to the previously mentioned reference genes. The graph displays median (dark lines), 25–75th percentile (boxes), interquartile ranges
(whiskers), and outliers (small, dark circles) from the CD3+ and CD19+ sorted cells of five healthy individuals, cell lines (Jurkat, CEM, HL60, K562,
and BJAB), and 11 patients with leukemia. Average values from the PBMCs obtained from the five healthy volunteers were used as controls. Statis-
tical significances are shown between both groups. Experiments were carried out at least twice.
BJAB JURKAT CEM K562 HL60
CTRL 100.00 100.00 100.00 100.00 100.00



















Figure 2 rhWNT4 inhibits cell viability in leukemia-derived cell
lines. Percentage of cell viability was measured in leukemia-derived
cell lines after stimulation with 200 ng/mL of recombinant human
WNT4 (rhWNT4) for 24 h in culture. Percentage of cell viability were
obtained using the optical density (OD) values of each unstimulated
cell line as 100% cell proliferation. Percentage of cell proliferation
was measured using WST-1 at 440 nm.
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marrow of patients with acute lymphoblastic leukemia
(ALL) and acute myeloblastic leukemia (AML). Add-
itionally, to assess the contribution of lymphocytes to
the WNT4 expression observed in the PBMCs, we iso-
lated T- and B-lymphocytes from five healthy individuals
by flow cytometry sorting, and measured WNT4 expres-
sion in these cells by real time-PCR. Normalization was
performed using ACTB, RPL32, and RPS18 as reference
genes, and relative expression analysis of the ALL and
AML bone marrow samples was performed using
PBMCs as the control (set as 1).
Figure 1C shows that CD19+ cells are the major
WNT4 producing cells (~15–20-fold), and that CD3+
cells express levels similar to PBMCs (~0.86-fold). Inter-
estingly, of the 11 BM cells from the patients with
leukemia included in the study, ten showed very low ex-
pression of WNT4; this trend became more strongly evi-
dent when compared with the control CD19+ cells.
In summary, leukemia-derived cell lines and bone
marrow cells from patients with leukemia show a statis-
tically significant decrease in the expression of WNT4
when compared with the expression in PBMCs from
healthy individuals.
Recombinant human WNT4 inhibits cell viability in
leukemia
Because we showed that WNT4 was more highly
expressed in mature lymphocytes derived from healthy
volunteers, and that its expression decreased in imma-
ture leukemia-derived cells, it was in our interest to de-
termine the biological effects of WNT4 in leukemia-
derived cells.
To do this we used BJAB, Jurkat, CEM, K562, and
HL60 cell lines as models. We cultured 5 × 103 cells in
96-well plates in the presence of 200 ng/mL of commer-
cially available recombinant human WNT4 (rhWNT4).
After 24 h of incubation, we measured the percentage of
cell viability by adding WST-1 to the culture medium.
Percentage of cell viability was calculated by taking the
optical density (OD) values of cells, using the value from
those without treatment as 100%. Incubation of
leukemia-derived cells with rhWNT4 drastically affectstheir growth in culture; all tested cell lines exhibited a
decrease in their percentage of cell viability when treated
with rhWNT4 ranging from 61.00–40.15% (Figure 2).
Restoration of WNT4 expression in BJAB cells inhibits cell
growth
To corroborate the effect observed on cell viability by
the addition of rhWNT4 to leukemia-derived cell lines,
we decided to restore WNT4 expression in leukemia-
derived cells. Because WNT4 is expressed mainly in ma-
ture B cells, we thought that the best candidates to
analyze the effect of WNT4 restoration would be the
BJAB cells, the only leukemia model cell line in our ex-
periments that were CD19+. To restore WNT4 expres-
sion, we used an inducible lentiviral expression system
(Clontech, additional detail provided in Materials and
Methods) in which the presence of Doxycycline (Doxy)
activates the expression of WNT4. First, to determine
whether WNT4 was successfully expressed after Doxy
treatment, RNA and total protein were obtained after
48-h of Doxy treatment; qRT-PCR and western blot as-
says were performed on these samples (see Figure 3).
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Figure 3 Endogenous restoration of WNT4 in BJAB cells. Overexpression of WNT4 in the leukemia-derived BJAB cell line was performed by
using a Doxycycline (Doxy)-inducible lentiviral expression system. After a 48-h incubation with Doxy, WNT4 expression was confirmed using qRT-
PCR (A), and western blot assays (B). A) Graphs showing the amplification curves obtained for WNT4 and RPS18 in BJAB-Tet-WNT4 cells cultured
in the presence or absence of Doxy. The WNT4 normalized relative ratio was calculated utilizing the non-treated BJAB-Tet cells as a control (set as
1), and by using ACTB, RPL32 and RPS18 as reference genes in two independent experiments. B) Western blot assays (50 μg total protein) showing
the presence of WNT4 protein after a 48-h incubation with Doxy; beta actin (ACTB) was used a protein loading control. C & D) Relative expression
levels of WNT4 were measured by qRT-PCR in PBMCs from healthy volunteers, CD3+ and CD19+ sorted cells obtained from healthy volunteers
(C), as well as in parental BJAB cells and in BJAB WNT4-expressing cells (D). The average values of PBMCs (in C) and CD19+ sorted cells (in D)
were used as controls. The graph depicts the means obtained with all reference genes ± standard deviations (SD).
García-Castro et al. BMC Cancer 2013, 13:557 Page 5 of 14
http://www.biomedcentral.com/1471-2407/13/557cells infected with pLVX-Tet On vector alone, and in
those infected with both pLVX-Tet On and pLVX-Tight-
Puro-WNT4 vectors after cultivation in the presence or
absence of Doxy for 48 h. Unexpectedly, as can be ob-
served in Figure 3A, an increase in WNT4 expression at
the mRNA level was observed in the absence of Doxy
(1.77 × 103); however, WNT4 expression increased
strongly (49.75 × 103-fold) in BJAB-Tet-WNT4 in the
presence of Doxy. The WNT4 normalized relative ratio
was calculated using the values from BJAB-Tet cells as a
control and RPS18, RPL32, and ACTB as reference
genes. Furthermore, as shown in Figure 3B, WNT4 ex-
pression was confirmed at the protein level after 48 h ofDoxy incubation. Despite the WNT4 expression ob-
served at the mRNA level in the BJAB-Tet-WNT4 cells
cultivated in the absence of Doxy, WNT4 expression at
the protein level could only be clearly observed after
48 h of Doxy treatment. To compare the expression
levels obtained with our inducible WNT4 system with
those of normal cells, we performed qPCR on samples
from PBMCs, T-cells (CD3+), B-cells (CD19+), BJAB-
TET-WNT4 cells treated 48 h with Doxy, and parental
BJAB cells. As can be observed in Figure 3C (left panel)
and according to Figure 1C, relative WNT4 expression
(as normalized to the level in the average of PBMCs
from five healthy individuals) showed a lower level of
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cells express approximately 25.43 ± 11.19-fold higher.
Furthermore, by normalizing to CD19+ cells (Figure 3C,
right panel), we observed that BJAB-Tet-WNT4 cells in
the presence of Doxy have a 2.7 ± 1.39-fold increase in
WNT4 expression. These results show that induction of
WNT4 in BJAB-Tet-WNT4 cells caused only ~2.5 times
more expression of WNT4 than the levels found in the
B-cells of healthy subjects.
After ensuring that WNT4 was successfully expressed
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Figure 4 Restoration of WNT4 in BJAB inhibits cell growth. A) Percent
48-h incubations with Doxycycline (Doxy). We also included parental BJAB
sured by adding WST-1 to the cell cultures for 2 h and reading the absorba
line of non-treated cells was set as 100% of cell proliferation. B) BJAB-Tet-W
counted every 24 h. The parental BJAB cell line was included as control.ligand on BJAB-cell viability and proliferation. We cul-
tured parental BJAB, BJAB-Tet, and BJAB-Tet-WNT4
cells in the absence or presence of Doxy for 24- and
48 h. Subsequently, WST-1 was added to cell cultures
and incubated for 2 h at 37°C before absorbance was
read at 440 nm. Percentage of cell viability was calcu-
lated using the OD values of cells growing in the ab-
sence of Doxy as 100% (0 h). As shown in Figure 4,
Doxy induces a very weak increase in cell viability at
24 h and reduces the viability rate slightly after 48 h in












age of cell viability was measured in BJAB-Tet-WNT4 cells after 24- and
and BJAB-Tet cells as controls. Percentage of cell viability was mea-
nce of treated and untreated cells at 440 nm. The value of each cell
NT4 cells cultivated for 72 h in the presence or absence of Doxy were
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Tet-WNT4 cells after 24-h (54.11%) and 48-h (33.84%)
incubation with Doxy. The latter result suggests that
WNT4 expression in BJAB cells reduces their viability;
however, because WST-1 assays indicate the number of
metabolically active cells, we asked whether cell prolifer-
ation was also affected by WNT4 expression. To do this,
parental BJAB and BJAB-Tet-WNT4 cells were cultured
in the absence or presence of Doxy for 72 h, and the
number of cells was measured for each 24-h period. As
can be observed in the cell counts plotted in Figure 4B,
the growth of parental BJAB cells with or without Doxy
exhibit similar proliferation curves, indicating that Doxy
did not modify the growth of parental BJAB cells. The
growth of BJAB-Tet-WNT4 cells in the absence of Doxy
exhibits behavior similar to that observed in parental
BJAB cells; in contrast, cell growth in BJAB-Tet-WNT4
cells was drastically decreased after 24 h of incubation
with Doxy (see cell counts at 24 and 48 h). Note that the
first 24-h of BJAB-Tet-WNT4 cell growth with or with-
out Doxy follows nearly the same proliferation rate; one
reason for this observation is that WNT4 ligand produc-
tion and secretion takes at least 24 h after the addition
of Doxy. Furthermore, we observed that after 48 h,
Doxy-treated BJAB-Tet-WNT4 cells recovered prolifera-
tion, but at a lower rate. Overall, these results confirm
the anti-proliferative role played by WNT4 in BJAB
cells.
WNT4 does not promote apoptosis, but strongly
modulates the cell cycle
A question that emerged from the previous set of exper-
iments was whether the decreased viability induced by
WNT4 expression in BJAB cells was due to an inhibition
in cell proliferation or an induction of apoptosis. To de-
termine this, we measured the apoptotic rate of parental
BJAB, BJAB-Tet, and BJAB-Tet-WNT4 cells grown in
the presence of Doxy to induce WNT4 expression.
Figure 5A shows that Doxy alone exerts no effect on
apoptosis in parental BJAB or BJAB-Tet cells, even after
48 h of incubation (Figure 5A). Interestingly, the WNT4
expression triggered by Doxy in BJAB-Tet-WNT4 cells
induces a slight, but not significant, increase in the
apoptosis rate (only 2%). Because we did not observe a
considerable impact on apoptosis, our next interest was
to elucidate whether WNT4-induced expression modu-
lates the cell cycle. To address this point, parental BJAB,
BJAB-Tet, and BJAB-Tet-WNT4 cells were cultured in
the presence of Doxy for 48 h to maintain the same con-
ditions for WNT4 expression, then, we analyzed total
DNA content using flow cytometry to determine the size
of cell populations in the different cell-cycle phases. It is
worth noting that prior to seeding the cells for this ex-
periment, cells were cultured for 24 h with low levels(2%) of Fetal bovine serum (FBS) in an attempt to
synchronize their growth before being seeded as usual
with 10% FBS. As shown in Figure 5B, 61.98% of paren-
tal BJAB cells accumulated in G1 phase after 48 h Doxy
treatment, compared with 49.49% of BJAB-Tet cells and
93.57% of BJAB-Tet-WNT4 cells. The data were ana-
lyzed using the cell cycle tool from the Flowjo v7.6.5
software, which showed a more pronounced effect of G1
arrest after Doxy treatment (Figure 5C). These observa-
tions led us to conclude that the inhibition of cell prolif-
eration mediated by WNT4 expression is due to cells
arresting in the G1 phase of the cell cycle.
Inhibition of cell proliferation by WNT4 does not activate
the canonical pathway
To determine whether the growth inhibition in BJAB
cells observed after WNT4 restoration was mediated by
activation of the canonical β-catenin pathway, we ana-
lyzed the expression of several reported target genes for
this pathway by qRT-PCR. We determined the mRNA
expression of AXIN2, JUN, MYC, CCND1, FOSL1, and
SURVIVIN in parental BJAB and in BJAB-Tet-WNT4.
As can be observed in Figure 6, none of the previously
mentioned genes were activated by restoring WNT4;
instead, nearly all of the genes, with the exception
of SURVIVIN, demonstrated decreased expression in
WNT4-expressing BJAB cells. These results indicate that
the effect of WNT4 on BJAB cell growth may not medi-
ated by the stabilization of β-catenin and, consequently,
activation of the canonical pathway.
FZD6, partner of WNT4, is expressed in lymphoid but not
myeloid cell lines
FZD6 is the sole Frizzled (FZD) receptor that has been
linked to WNT4 in hematopoietic cells [15]; therefore,
we thought it important to establish whether the action
of WNT4 in our cell model was due to binding to
FZD6. First, we measured the mRNA levels of this re-
ceptor by qRT-PCR, and then performed expression ana-
lyses (ΔCP). We found that FZD6 is most clearly
detected in BJAB, Jurkat, and CEM cells. Interestingly,
myeloid cell lines K562 and HL60 express the lowest
levels of FZD6 mRNA (Additional file 1: Figure S1A).
To confirm these observations, we additionally detected
the FZD6 receptor at the protein level by flow cytome-
try. As illustrated in Additional file 1: Figure S1B, high
expression of FZD6 was observed in lymphoid Jurkat,
CEM, and BJAB cell lines. On the other hand, myeloid
cell line K562 exhibited very low levels of this receptor,
and HL60 levels were undetectable. These results sug-
gest that inhibition of cell proliferation mediated by
WNT4 may not be dependent on the binding of this lig-
and to FZD6, especially not in cell lines of myeloid
origin.
G1 = 58.89 %
G2 = 28.93 %
S = 12.18 %
G1 = 45.83 %
G2 = 39.54 %
S = 14.63 %
G1 = 97.58 %
G2 = 0.89 %
S = 1.73 %
BJAB + DOXY BJAB-Tet-WNT4 + DOXYBJAB-Tet + DOXY
BJAB + DOXY BJAB-Tet-WNT4 + DOXYBJAB-Tet + DOXY










61.98% 28.53% 49.49% 40.01% 93.57% 1.91%
Figure 5 Restoration of WNT4 in BJAB cells does not promote apoptosis, but modulates the cell cycle. A) Percentage of apoptosis was
determined by using Annexin-V-Fluos/Propidium Iodide in BJAB-Tet-WNT4 cells after 48-h incubation in the presence or absence of Doxycycline
(Doxy). We also included parental BJAB and BJAB-Tet cells as control. A total of 20,000 events were counted. B) Parental BJAB, BJAB-Tet, and
BJAB-Tet-WNT4 cells were cultured in presence of Doxy for 48 h. Afterward, flow cytometric analysis of the DNA content was conducted to deter-
mine cell populations in the different cell-cycle phases. Dotplots and histograms were obtained with Attune Cytometric Software ver 2.1.0, G1
and G2 populations are shown. C) Histograms obtained by analyzing cell cycle with FlowJo software. A total of 20,000 events in gated singlets
were counted.
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WNT-mediated signal transduction pathways have long
been recognized for their roles in regulating embryonic
development; this pathway additionally plays a promin-
ent role in stem cell biology, including self-renewal,
pluripotency, and differentiation [7,24]. However, more
recently it has also been linked to cancer and humandisease processes [2,25]. Specifically, in leukemia there is
experimental evidence demonstrating the influence of
WNT pathway components on the oncogenic growth of
disease from both myeloid and lymphoid origin
[7-10,12], but there is a very limited number of publica-
tions on WNT4 expression and its role in the biology of
these cells. Therefore, we were interested in probing
AXIN2 JUN MYC CCND1 SURVIVIN
BJAB 1.00 1.00 1.00 1.00 1.00 1.00






















Figure 6 Inhibition of cell growth through WNT4 did not
involve the canonical pathway. Relative expression levels of AXIN2,
MYC, JUN, CCND1, FOSL1, and SURVIVIN were determined by qRT-PCR
in parental BJAB and BJAB-Tet-WNT4 cells. Quantification was calcu-
lated by normalizing with BJAB (set as 1) and using ACTB, RPS18, and
RPL32 as reference genes. The graph shows the means obtained
with reference genes ± Standard deviations (SD).
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hematopoietic cells.
Our results show that WNT4 is expressed in normal
cells, predominantly in B-cells, but that its expression is
strongly reduced in leukemia-derived cell lines and in
BM cells from patients with leukemia. In accordance
with this observation, Lu et al. reported that WNT4
levels are decreased in patients with Chronic lympho-
cytic leukemia (CLL), compared with healthy control B-
cells. It has been reported that WNT4 is poorly
expressed in endometrial and squamous cell carcinomas
[18,26]; additionally, it has been observed that WNT4 is
downregulated in human anaplastic thyroid carcinomas
[27]. In contrast, Memarian A, et al., using semi-
quantitative PCR, found higher expression of WNT4 in
patients with CLL when compared with that of normal
subjects [22]; however, the authors did not find this dif-
ference in patients with Acute lymphoblastic leukemia
(ALL) [23]. The different WNT4 expression pattern ob-
served between normal and the malignant cells suggests
that this ligand could be essential for normal cell devel-
opment. Regarding WNT4 protein expression level, it is
important to note that we observed significant WNT4
protein expression in PBMCs, but relatively lower than
the amount observed at the mRNA level. We hypothe-
sized that this may be due to the fact that B lymphocytes
are the major WNT4-expressing cells, which comprise
only 5 – 15% of the lymphocytes in the PBMC popula-
tion. Additionally, it could be that this protein is actively
secreted, for we did not use any secretion inhibitor in
our experiments.
To our knowledge, our group is the first to report that
WNT4 inhibits the cell growth of leukemia-derived celllines. We were able to demonstrate this effect by restor-
ing WNT4 using an inducible lentiviral overexpression
system and the addition of a commercially available re-
combinant human WNT4 protein. Some reports support
the anti-proliferative action of non-canonical WNT li-
gands in cancer; for example, it has been demonstrated
that restoration of WNT7a expression reverses cellular
transformation in non-small cell lung cancer (NSCLC)
by mediating growth inhibition and promoting cell dif-
ferentiation. Inhibition of cell proliferation due to the
restoration of WNT7a has also been observed in PC12
cells and leukemia-derived cell lines [28-32]. In contrast,
WNT4 has been reported to enhance murine
hematopoietic progenitor cell expansion [15] and, inter-
estingly, overexpression of WNT4 has been associated
with differentiation in human primary endometrial stro-
mal cells (HESCs) [33]. It has been also reported that
WNT4 interferes with Ras-induced actin cytoskeleton
reorganization; it is known that aberrant motility and in-
vasive ability are relevant hallmarks of malignant tumor
cells [27].
Although we determined WNT4 inhibited cell prolif-
eration in our cell culture model of inducible WNT4 ex-
pression, no effect on apoptosis was observed. It appears
that WNT4 expression strongly modulates the cell-cycle
phases, because an arrest in G1 and S phases was ob-
served after the restoration of WNT4 expression. Con-
trary to our findings, Heinonen et al. also found that
WNT4 highly induces the anti-apoptotic protein Bcl-XL,
but these authors did not find differences in cell-cycle
phases [15]. The discrepancy in these findings could be
caused by the use of different research models: while our
research has been conducted in human leukemia-
derived cells, Heinonen et al. employed a murine model.
By measuring diverse WNT target genes, we were able
to determine that inhibition of cell growth through
WNT4 does not involve the canonical pathway. There is
increasing evidence that WNT4 signals through a non-
canonical pathway in many cell types, such as β-cells
[34], human anaplastic thyroid carcinomas [27], murine
hematopoietic progenitor cells [15], and human pituitary
adenomas [35]. However, in Madin-Darby canine kidney
(MDCK) epithelial cells [17] and in endometrial stromal
cells [33], it has been observed that WNT4 operates via
both the non-canonical and the canonical pathways. An-
other report demonstrates that WNT4 inhibits β-
catenin/TCF signaling by redirecting beta-catenin to the
cell membrane [36].
Because the effects of WNT signaling are strongly
dependent on the nature of the Frizzled receptors
present [37], it was of great interest to us to attempt to
elucidate the receptor that was involved in the inhibition
of cell proliferation. To date in the scientific literature, it
has been reported that WNT4 binds to the FZD6
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cently, it was reported to also bind to PTK7/Otk to in-
duce non-canonical signaling [38]. We report here that
WNT4 cell-growth inhibition in leukemia-derived cells
appears to be FZD6-independent, at least in myeloid cell
lines (K562 and HL60), because this receptor is not
expressed in these cells at the protein level. A clear ef-
fect on the inhibition of proliferation was observed in all
cases. In contrast to our observations, FZD6 expression
has been reported to be present in K562 and HL60 by
other authors [21,39]; however, in both reports, FZD6
expression was analyzed only at the mRNA level (North-
ern blot and PCR). This suggests that other receptors/
co-receptors must be involved in WNT4 signaling and
that the molecules involved are dependent on the cell
type.
We suggest that the maintenance of appropriate
WNT4 expression may also be critical for prevention
against tumor initiation. Interestingly, WNT4 overex-
pression in stromal cells (OP9-DL1–W4) was sufficient
to allow LN c-KitloSca-1+ cells to generate mature T-
cells [40]. It could be that the inhibition of WNT4-
mediated proliferation in leukemia-derived cells is due
to the regulation of genes that participate in controlling
proliferation and differentiation.
Conclusions
We showed that WNT4 expression is strongly reduced
in leukemia-derived cell lines and in blasts from patients
with leukemia compared with the expression in mature
blood cells from healthy individuals. Interestingly, restor-
ation of WNT4 expression inhibits cell growth in a non-
canonical manner and appears to be FZD6-independent.
Our results suggest that WNT4 could act as a tumor




This protocol was approved by Ethical and Research
Committee No. 1305 of the Centro de Investigación Bio-
médica de Occidente (CIBO) – Instituto Mexicano del
Seguro Social (IMSS), with registration number: R-2011-
1305-6. Authorization for the taking samples from pa-
tients with leukemia was obtained from the National
Health Research Committee (IMSS), with registration
number: R-2012-785-056. Written informed consent
from healthy volunteers and patients with leukemia (in
compliance with the Helsinki Declaration) was also re-
quired prior to blood/bone marrow sample collection.
Cell line culture
Human leukemia-derived cell lines BJAB (lymphoblasts
of acute B-cell leukemia- derived cells), Jurkat, CEM(lymphoblasts of acute T-cell leukemia), K562 (lympho-
blasts of erythroleukemia), and HL60 (promyeloblasts of
acute promyelocytic leukemia) were employed as study
models. Cells were suspended in RPMI medium-1640
supplemented with 10% Fetal bovine serum (FBS), peni-
cillin (100 U/mL), and streptomycin (100 μg/mL) at
37°C in a humidified atmosphere of 5% CO2. All of the
previously mentioned products were obtained from the
GIBCO™ Invitrogen Corporation.
Isolation of PBMC, bone marrow, and T- and B-cells
Peripheral blood mononuclear cells (PBMCs) obtained
from five healthy volunteers (10 mL of peripheral blood)
were isolated by density-gradient centrifugation with
Ficoll-Paque™ PLUS (GE Healthcare). The PBMCs were
resuspended in PBS and stained with an anti-CD3 anti-
body (sc-1179-FITC, Santa Cruz Biotechnology) to select
T-lymphocytes and an anti-CD19 antibody (sc-19650-
PE, Santa Cruz Biotechnology) to select B-lymphocytes.
After incubation with both antibodies, cells were
washed, and cells positive for CD3 or CD19 were sorted
on a FACSAria (Becton Dickinson). Bone marrow sam-
ples (1–2 ml) from patients with leukemia were also ob-
tained by density-gradient centrifugation with Ficoll.
General characteristics of patients with leukemia are in-
cluded in Additional file 2: Table S1.
Restoration of WNT4 with recombinant human protein
BJAB, Jurkat, CEM, K562, and HL60 cells were cultured
at a density of 0.5 × 104 cells in 96-well microtiter plates
in 200 μL of RPMI medium. Recombinant human
WNT4 (cat. no. 6076-WN; R&D Systems) was reconsti-
tuted in sterile Phosphate-buffered solution (PBS). The
recombinant protein was added at a final concentration
of 200 ng/mL; incubations at 37°C were performed for
24 and 48 h.
Cloning WNT4
The WNT4 open reading frame (ORF) (GeneID: 54361;
NM_030761.4) was amplified from epithelial cells de-
rived from human thymoma using the Expand High Fi-
delity PCR System (cat. no. 11 732 650 001; Roche
Applied Science) with the following set of primers: for-
ward 5′- GGC ACC ATG AGT CCC CGC TCG -3′,
and reverse: 5′- GCA GGG CTA GGC AGG CGG TCA
-3′. Afterward, the PCR product was run on a 1% agar-
ose gel and purified with the Vivantis GF-1 Gel DNA
Recovery kit (SKU GF-GD-050). The WNT4 ORF was
cloned into pGEM®-T Easy vector (cat. no. A1360).
The resulting construct was sequenced with the M13
Forward and Reverse primers (Invitrogen) using the Big-
Dye® Terminator Cycle Sequencing Kit (Applied Biosys-
tems). WNT4 ORF was isolated from the pGEM®-T Easy
vector using EcoRI restriction and subcloned into the
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Tight-Puro (cat. no. 632162; Clontech Laboratories,
USA). Prior to cloning, this vector was previously
unphosphorylated.
Lentivirus production and infection
To produce infectious viral particles, Lenti-X 293 T-cells
were transfected employing the Lentiphos HT™ Pack-
aging System (cat. no. 632151; Clontech Laboratories)
with lentiviral vectors pLVX-Tet-On Advanced and
pLVX-Tight-Puro-WNT4, which were used as described
by the manufacturer (Clontech Laboratories). After 48 h,
the supernatants were collected and checked with Lenti-
X GoStix (Clontech Laboratories) to determine whether
sufficient viral particles were produced prior to transdu-
cing target cells. The supernatants were filtered through
a 0.45-μm PES filter to eliminate detached cells, ali-
quoted, and subsequently stored at −80°C until use.
BJAB cells were first transduced with the pLVX-Tet-On
(regulator vector) and selected with G418 (cat. no.
631307; Clontech Laboratories), 500 μg/mL. The cells
were next transduced with pLVX-Tight-Puro-WNT4
and selected with Puromycin for 2 weeks (1 μg/mL).
After selection, cells were grown in the absence or pres-
ence of Doxy (750 ng/mL) to overexpress WNT4.
Primer design
Primer design for the WNT4 ligand was performed
using Oligo-Primer Analysis ver. 6.51 software (Molecu-
lar Biology Insights, Inc., USA) using sequences obtained
from the GenBank nucleotide database on the NCBI
website. Specific primers and some of their features are
listed in Table 1. Primers were synthesized by the Invi-
trogen Corporation.
qRT-PCR assays
Total RNA was isolated from 5 × 106 BJAB cells trans-
fected with the WNT4 DNA construct at 0, 4, 8, 16, and
24 h after treatment with Doxy. Isolation was performed
using the PureLink™ Micro-to-Midi Total RNA Purifica-
tion System (cat. no. 12183–018; Invitrogen) as sug-
gested by the manufacturer.
Total RNA was reverse-transcribed to cDNA using the
SuperScript™ III First-Strand Synthesis System primed
with oligo(dT) (cat. no. 18080051; Invitrogen). cDNA
synthesis was performed from 5 μg of total RNA. The
protocol was carried out as suggested by the
manufacturers.
Gene expression levels were analyzed by qRT-PCR.
Assays were performed with 2.0 LightCycler technology
using the LightCycler FastStar DNA Master PLUS SYBR
Green I kit (cat. no. 03515885001; Roche Applied Sci-
ence) as recommended by the manufacturers. Analysis
of gene expression was performed with LightCycler ver.4.1 software (LCS). RPS18 (d/ing: 18 s Ribosomal Pro-
tein), RPL32 (d/ing: ribosomal protein L32), and ACTB
(d/ing: Actin beta) were used as endogenous controls.
Relative quantification of target genes was determined
using the ΔΔCP method.
FZD6 expression analysis was carried out by ΔCP
(FZD6 CP - reference gene CP). It is very important to
point out that ΔCP is inversely proportional to the ex-
pression of the target gene.
Analysis was performed using the values obtained
from two independent RNA extractions done in
duplicate.
Western blot assays
Cells were lysed with RIPA buffer by sonication (15
pulses, 90% amp). Total extracts were incubated for
30 min at 4°C and subsequently obtained by centrifuga-
tion (14,000 rpm for 5 min at 4°C). Protein concentra-
tions were determined using the Bio-Rad DC Protein kit
(cat. no. 500–0114, Protein DC-BioRad; Bio-Rad Labora-
tories), and 50 μg of the extracts was electrophoresed in
12% SDS-PAGE. Proteins were then transferred onto a
PVDF membrane (Millipore) and incubated with 1%
Western blocking reagent (cat. no. 11921681001; Roche
Applied Science) to block nonspecific binding. Primary
antibody (anti-WNT4: cat. no. MAB4751, R&D Systems;
Actin: cat. no. sc-1616, Santa Cruz Biotechnology; α
tubulin: cat. no. sc-8035, Santa Cruz Biotechnology and
anti-beta 2 microgloblin: cat. no. ab15976, Abcam) was
incubated overnight at 4°C, and specific secondary anti-
body was incubated with the membrane for 1 h at room
temperature, followed by chemiluminescent detection
using Immobilon Western substrate (Millipore Corpor-
ation) with the ChemiDoc XRS (Bio-Rad Laboratories).
Measurement of cell viability
Cell viability was determined using WST-1 (cat. no. 11
644 807 001; Roche Applied Science). Absorbance of
treated and untreated cells was measured at 450 nm on
a microtiter plate reader (Synergy™ HT Multi-Mode Mi-
croplate Reader; Biotek, Winooski, VT, USA). The value
of untreated cells was used as 100% cell survival.
Apoptosis detection
Cell death was measured by flow cytometry using propi-
dium iodide (cat. no. P4864; Sigma-Aldrich) and
Annexin-V-FLUOS (cat. no. 1828681; Roche Applied
Science) as recommended by these manufacturers. Cells
were seeded at a density of 2.5 × 105 cells per flask in
10 mL RPMI medium with or without Doxy (750 ng/
mL). After a 72-h incubation, cells were washed with
PBS and incubated with annexin and propidium iodide
for 15 min; 20,000 events from each sample were
Table 1 Oligonucleotides used for the qRT-PCR analysis
Gene name Sequence accession number Primer sequence Primer location (Exon) Prod. length T°a
WNT4 ORF Wingless-type MMTV integration site family, member 4 NM_030761 F GGCACCATGAGTCCCCGCTCG 99–119 (1) 1055 60
R GCAGGGCTAGGCAGGCGGTCA 1158–1178 (5)
WNT4 Wingless-type MMTV integration site family, member 4 NM_030761 F GGAACTGCTCCACACTCGACTC 364–385 (3) 259 60
R CGCACATCCACAAACGACTGT 602–622 (4)
MYC V-myc myelocytomatosis viral oncogene homolog (avian) NM_002467.4 F CCAGCGCCTTCTCTCCGTC 1208–1226 (2) 302 60
R GGGAGGCGCTGCGTAGTTGT 1490–1509 (3)
JUN Jun proto-oncogene NM_002228.3 F TGGAAAGTACTCCCCTAACCT 2786–2806 (1) 250 60
R CTGAAACATCGCACTATCCTT 3015–3035 (1)
FOSL1/FRA1 FOS-like antigen 1 NM_005438.3 F AGGAACCGGAGGAAGGAACTG 554–574 (3) 199 60
R TGCCACTGGTACTGCCTGTGT 732–752 (4)
AXIN2 Axin 2 NM_004655.3 F AAAAAGGGAAATTATAGGTATTAC 2678–2701 (10/11) 277 54
R CGATTCTTCCTTAGACTTTG 2935–2954 (11)
CCND1 cyclin D1 NM_053056.2 F CCCCAACAACTTCCTGTCCTAC 866–887 (4) 236 60
R GCCCTCAGATGTCCACGTC 1083–1101 (5)
SURVIVIN/BIRC5 Homo sapiens baculoviral IAP repeat containing 5 NM_001012271.1 F TGAGCTGCAGGTTCCTTATCTG 1057–1078 (5) 234 60
R GAATGGCTTTGTGCTTAGTTTT 1269–1290 (5)
RPL32 Ribosomal protein L32 NM_000994.3 F GACTTGACAACAGGGTTCGTAG 213–234 (3) 320 60
R ATTTAAACAGAAAACGTGCACA 511–532 (4)
RPS18 Ribosomal protein S18 NM_022551.2 F CGATGGGCGGCGGAAAA 105–121 (2) 283 58
R CAGTCGCTCCAGGTCTTCACGG 366–387 (5)
ACTB Beta Actin NM_001101.3 F TCCGCAAAGACCTGTACG 950–967 (5) 298 60
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Cell cycle analysis
For cell cycle analysis, we used 2 different kits: the
BD Cycletest™ Plus DNA Reagent kit (cat. no.
340242; Becton, Dickinson and Company), and the
Cell Cycle Assay kit (Fluorometric-Green, cat. no.
ab112116, Abcam). Both were used following the
manufacturer’s instructions. DNA QC particles (cat.
no. 349523) were used for verification of instrument
performance and quality control of BD FACS™-brand
flow cytometer employed in the DNA analysis. For
each sample, at least 20,000 events were acquired in
the singlet’s region and data were analyzed using the
cell cycle tool from the Flowjo v7.6.5 software pack-
age (Tree Star Inc., OR, USA).
Flow cytometry analysis
A total of 1 × 106 cells were suspended in 100 μL of
Phosphate-buffered saline (PBS), and anti-human Frizzled-
6 antibody (cat. no. AF3149; R&D Systems) was added.
After 30 min at room temperature, the cells were washed
once and resuspended in PBS. Then, phycoerythrin-
conjugated donkey anti-goat IgG (cat.no. F0107; R&D Sys-
tems) was added. We incubated the cells for an additional
30 min. Finally, the cells were washed twice and were read
in the cytometer.
Statistical methods
The data obtained are shown as mean ± Standard de-
viation (SD). Post-hoc tests (Tukey HSD, Bonferroni,
and Dunnett 3 T) were utilized for multiple compar-
isons between groups and one-way analysis of vari-
ance (ANOVA) was employed to compare means
between more than two different groups. Compari-
son between two groups was performed using a two-
tailed T-test. Only p values of <0.05 were considered
significant. Statistical analysis was performed with
Predictive Analytic SoftWare (PASW) (Statistics ver.
18.0).
Additional files
Additional file 1: Figure S1. FZD6, partner of WNT4, is expressed in
lymphoid but not myeloid cell lines. A) FZD6 expression levels (ΔCP)
measured by qRT-PCR in normal PBMCs and leukemia-derived cell lines
(BJAB, Jurkat, CEM, K562, and HL60). ΔCP values were calculated utilizing
ribosomal Protein L32 (RPL32) and ribosomal Protein S18 (RPS18) as refer-
ence genes. The graphs depict the means and subsequent standard devi-
ations (SD) obtained with all reference genes. B) Representative
histograms of flow cytometry data for FZD6. Numbers at the upper part
of each curve represent the geometric median for each condition: control
unlabeled cells (red curve); secondary antibody (black curve), and FZD6
antibody (green curve).Additional file 2: Table S1. General Characteristic of patients with
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